CD274 and neoplasm: Patients with PD-L1 positive tumors (as defined by ≥1% of immune cells immunohistochemistry (IHC)-staining positive within the tested tumor area) showed a median PFS of 13.8 months for the combination therapy compared to 7.2 months for the sunitinib alone.